The Independent Standard for Pharmaceutical Reimbursement Risk
A Committee-Based Rating System Calibrated to Historical HTA Outcomes Across US, EU4, UK and Japan.
What MARA Rating Provides
MARA Rating is an independent, standardized assessment of pharmaceutical market access risk.
Regulatory approval does not guarantee reimbursement.
HTA agencies and payers act as a second gate.
MARA synthesizes evidence across 10 payer-relevant domains — including comparative effectiveness, safety, cost-effectiveness, budget impact, and evidence strength — into a single, comparable rating band (A++ to C).
The objective is not to replace judgment.
It is to reduce variance, surface hidden constraints, and provide a defensible benchmark before capital is committed.
How the MARA Rating Is Determined
Structured evaluation across 10 calibrated domains
Public, verifiable evidence sources only
Committee-based judgment; no single analyst determines outcome
Minutes recorded and conflict-of-interest controls enforced
Calibrated against historical HTA outcomes
Subject to defined surveillance and rating actions
Used in High-Stakes Decision Contexts
MARA Ratings are designed to support:
Pre-deal due diligence and valuation stress-testing
Phase 2 → Phase 3 investment decisions
Pre-launch pricing and reimbursement governance
Portfolio reprioritization
Investor memoranda and capital allocation discussions
Core principle:
If this decision is challenged later, what independent reimbursement benchmark was relied upon?
Rating Products
Single-Asset MARA Rating (Internal Use License)
Full committee-based rating with drivers, rationale, benchmarking, and surveillance status.
Therapeutic Area Benchmark Pack
Side-by-side rating comparison across assets within a defined therapeutic area.
Portfolio Access (Institutional License)
Structured access to multiple ratings and rating updates across defined asset groups.
Note: Public display of a MARA Rating requires a valid Display License.
Governance & Calibration
Published methodology framework
Defined rating action categories
Committee charter and conflict-of-interest controls
Calibration against retrospective HTA outcomes
Ongoing surveillance and periodic review
Rating Committee Charter
Annual Calibration Process
Obtain an independent reimbursement risk benchmark.
Methodology Overview (2 Minutes)
This short overview explains the structured evaluation process, committee governance, and calibration principles underlying the MARA Rating.
Check out our Youtube channel here.
Contact a MARA Analyst
Have a molecule in mind—or just a market access pharma question? Send us a note to sales@mararating.com and one of our analysts will reply within one business day. All inquiries are confidential.
"*" indicates required fields
Market Access & Capital Risk Insights
Surveillance Update for June 26: 12 MARA Ratings Reassessed Following Regulatory Approvals
Overview Between February and June 2026, twelve drugs previously rated by MARA received new regulatory approvals — from the FDA
June 2026 MARA Ratings: 17 New Assessments Across Three Risk Tiers
Overview MARA Rating completed 17 new Reimbursement Risk Assessments in June 2026. The assets span nine therapeutic areas: oncology, obesity,
Medicare Drug Price Rule May Target Subcutaneous Keytruda and Opdivo: What Does It Mean for Market Access?
Summary A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and
Nine HTA decisions. Seven correct MARA Rating predictions. What we got right, and what we missed.
MARA Rating — Back-test series, June 2026 We built MARA to answer one question before the decision arrives: given this
GSK Acquires Nuvalent for $11 Billion in Pre-Approval NSCLC Bet
Deal Summary On June 9, 2026, GSK announced the acquisition of Nuvalent for $11 billion — paying $124 per share,
Roche and Nurix Partner on BTK Degrader Bexobrutideg in $700M Deal
On June 8, 2026, Roche and Nurix Therapeutics announced a clinical collaboration for bexobrutideg — a BTK protein degrader in